Matthew Biegler
Stock Analyst at Oppenheimer
(1.01)
# 3,651
Out of 4,855 analysts
79
Total ratings
28.99%
Success rate
-16.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Outperform | $10 → $9 | $1.35 | +566.67% | 2 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.42 | +533.80% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $4.46 | +393.27% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $9.32 | +28.76% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $0.22 | +3,474.62% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $7.53 | +497.61% | 4 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $112.46 | +2.26% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $21.72 | +144.01% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $10.55 | +212.80% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $1.52 | +1,215.79% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.36 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $127.85 | -2.23% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $11.04 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.25 | +93.10% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.83 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.60 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.19 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.90 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.05 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $8.37 | +4,201.08% | 1 | Nov 30, 2022 |
Acrivon Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.35
Upside: +566.67%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.42
Upside: +533.80%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $4.46
Upside: +393.27%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $9.32
Upside: +28.76%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.22
Upside: +3,474.62%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $7.53
Upside: +497.61%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $112.46
Upside: +2.26%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $21.72
Upside: +144.01%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.55
Upside: +212.80%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.52
Upside: +1,215.79%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.36
Upside: -
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $127.85
Upside: -2.23%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $11.04
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.25
Upside: +93.10%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.83
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.60
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.19
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.90
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.05
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $8.37
Upside: +4,201.08%